William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

William Blair analyst Matt Phipps has initiated coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating. This marks a significant endorsement for the company in the financial markets.